No Data
A-share market review: The Shanghai Composite Index opened lower and fell by 1.39%! The medical sector bucked the trend and rose.
Glory Times on November 12th | A-shares main indices fluctuated lower in early trading today, continued downward in the afternoon; as of the close, the Shanghai Composite Index fell by 1.39% to 3421 points, the Shenzhen Component Index fell by 0.65%, and the Chinext Price Index fell by 0.07%. The total turnover for the day was 2.55 trillion yuan, an increase of 43 billion yuan from the previous trading day, with nearly 3800 stocks declining across the entire market. On the market, the insurance sector declined, hubei biocause pharmaceutical hit the limit down; the aerospace and aviation sector retreated significantly, avic shenyang aircraft fell nearly 8%; the Huawei Euler sector weakened, Kirin Trust plunged nearly 10% at one point; the shipbuilding sector weakened, china shipbuilding industry group power led the decline; education, photolithography glue, and AI corpus sectors weakened.
Express News | Pfizer's China region president: will continue to deepen the Chinese market in the next 5 years.
china meheco group (600056.SH): Subsidiary obtains approval notice for pharmaceutical supplementary application.
On October 28th, China Meheco Group (600056.SH) announced that its wholly-owned subsidiary, Hainan General Sanyo Pharmaceutical Co., Ltd. (referred to as "Sanyo Pharmaceutical"), has received the approval notice for the supplementary application of pharmaceutical injection of Roshantidine Hydrochloride Acetate (referred to as "the pharmaceutical") issued by the National Medical Products Administration. This pharmaceutical is a histamine H2 receptor antagonist, which, through ester hydrolysis in the body, rapidly converts to the metabolite Roshantidine, effectively inhibiting the basal gastric acid secretion of animals and the stimulated gastric acid secretion. The pharmaceutical is suitable for upper gastrointestinal bleeding (caused by peptic ulcers,
Express News | China Meheco Group: Subsidiary pharmaceuticals passed generic drug consistency evaluation.
The first batch of pharmaceutical fund's third quarter report is released! Shareholding in US stocks reduced, while increasing holdings in Hong Kong stocks and A-shares.
The first batch of fund managers exposed in the third quarter medical investment strategy, significantly increased the proportion of innovative drugs, especially the position of Hong Kong-listed innovative drugs with greater flexibility.
Full report for the third quarter of 2024
No Data
No Data